Hyundai ADM Bio Inc. (KOSDAQ:187660)

South Korea flag South Korea · Delayed Price · Currency is KRW
18,670
0.00 (0.00%)
At close: Feb 27, 2026
878.00%
Market Cap 1.02T
Revenue (ttm) 9.74B
Net Income (ttm) -20.10B
Shares Out 54.76M
EPS (ttm) -475.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 33,271,020
Average Volume 20,486,383
Open 18,990
Previous Close 18,670
Day's Range 15,560 - 20,150
52-Week Range 1,118 - 20,350
Beta 1.11
RSI 97.13
Earnings Date Mar 16, 2026

About Hyundai ADM Bio

Hyundai ADM Bio Inc., a contract research organization, provides clinical services in Asia. It offers clinical development services, such as medical writing, clinical operation, late phase study, data management, biostatistics, and regulatory affairs. The company also provides pharmacovigilance services, which include case processing and safety reporting, safety and risk management plans, aggregate reporting, literature screening, and medical device vigilance; and quality assurance services. In addition, it develops, manufactures, and sells med... [Read more]

Industry Commercial Physical and Biological Research
Founded 2003
Employees 160
Stock Exchange KOSDAQ
Ticker Symbol 187660
Full Company Profile

Financial Performance

In 2024, Hyundai ADM Bio's revenue was 9.74 billion, a decrease of -29.33% compared to the previous year's 13.79 billion. Losses were -20.10 billion, 576.6% more than in 2023.

Financial Statements

News

There is no news available yet.